Sanofi-Aventis co-opts Piwnica to board
This article was originally published in Scrip
Executive Summary
The French pharmaceuticals group Sanofi-Aventis has co-opted Carole Piwnica to its board. She trained as a lawyer and is a member of the bar of New York and Paris. Since 2006, Ms Piwnica has been chief executive officer of Naxos UK, a company specialising in private equity consulting. She is also a board member of Eutelsat, a French satellite provider, Louis Delhaize, a Belgian distribution company, and Aviva, a UK-based insurance company.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.